Concert Pharmaceuticals to Present at Three Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2015 Healthcare Conference on September 9, 2015 at 3:30 p.m. EDT in Boston, MA; The Baird 2015 Healthcare Conference on September 10, 2015 at 9:05 a.m.... more →
Posted in: Press

Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering are to be sold by Concert. Wells Fargo and JMP Securities are acting as joint book-running managers for the proposed offering. Concert intends to grant the underwriters... more →
Posted in: Press

Concert Pharmaceuticals Appoints James V. Cassella as Chief Development Officer

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert’s product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities. “Jim... more →
Posted in: Press

Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 22, 2014. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified... more →
Posted in: Press

Concert Pharmaceuticals Announces Positive CTP-354 Data

Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight on the commercial potential of the candidate once it is successfully developed and... more →
Posted in: Press

Concert Pharmaceuticals Achieves $2M Milestone Collaborating With Avanir Pharmaceuticals

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment... more →
Posted in: Press